



NDA 022051/S-021

**SUPPLEMENT APPROVAL**

GlaxoSmithKline Consumer Healthcare Holdings (US) LLC d/b/a Haleon  
Attention: Misha Mehta  
Senior Associate, U.S. Regulatory Affairs  
184 Liberty Corner Road  
Suite 200  
Warren, NJ 07059

Dear Misha Mehta:

Please refer to your supplemental new drug application (sNDA) dated and received on May 3, 2023, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Flonase Sensimist Allergy Relief (fluticasone furoate) nasal spray, 27.5 mcg per spray.

This “Prior Approval” supplemental new drug application provides for several labeling updates (language and graphics) and removal of quick start guide component.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**LABELING**

Submit final printed labeling (FPL) as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the enclosed labeling described in the table below and must be in the “Drug Facts” format (21 CFR 201.66), where applicable. We remind you to remove the “NEW LOOK” flag from the labeling 6 months after the marketing start date.

<b>Submitted Draft Labeling</b>	<b>Date Submitted</b>
<b>NDA 022051 (Flonase Sensimist Allergy Relief)</b>	
120 sprays count Lid	10/20/23
2 x 120 sprays count Lid	10/20/23
Front bottle label	10/20/23
Back bottle label	10/20/23

<b>Submitted Draft Labeling</b>	<b>Date Submitted</b>
Extended Content Label (includes the DFL)	10/20/23
Leaflet	10/20/23

Submit the FPL electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 022051/S-021.**” Approval of this submission by FDA is not required before the labeling is used.

## **DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your FPL, the content of labeling (Drug Facts) should be submitted in SPL format as described at FDA.gov.<sup>2</sup> Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

## **PATENT LISTING REQUIREMENTS**

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

---

<sup>2</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Your product is a Part 3 combination product (21 CFR 3.2(e)); therefore, you must also comply with postmarketing safety reporting requirements for an approved combination product (21 CFR 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at [FDA.gov](http://FDA.gov).<sup>3</sup>

If you have any questions, call Phong Pham, PharmD, MBA, Regulatory Project Manager, at (301) 837-7656 or email at [Phong.Pham@fda.hhs.gov](mailto:Phong.Pham@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Nushin Todd, MD, PhD  
Director  
Division of Nonprescription Drugs I  
Office of Nonprescription Drugs  
Center for Drug Evaluation and Research

ENCLOSURES:

- Carton and Container Labeling

---

<sup>3</sup> <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

NUSHIN F TODD  
11/15/2023 01:48:02 PM